NOW Boswellia Extract is what we hand a first-time buyer who wants the right thing without overthinking it. The boswellia aisle is unusually easy to buy wrong — most sub-$15 bottles are unstandardised resin powder that say "Boswellia 500 mg" and tell you nothing about the boswellic acids that actually work. NOW sidesteps that trap with a genuinely standardised extract: 65% boswellic acids, a real and stated active figure, co-formulated with a turmeric co-factor, manufactured in a GMP facility under NOW's in-house QC labs, at roughly $11 a month — a price that undercuts almost every clinician brand on the list. It isn't the AKBA-enriched material the strongest trial used (that's Life Extension 5-LOXIN, #2), and that's the only reason it isn't scored higher. But for most buyers, a tested, standardised, fairly-priced bottle beats chasing the last increment of AKBA precision. Here's the full breakdown.
Check on AmazonAffiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Boswellia guide →Standardised to 65% boswellic acids — a real, stated active figure, not the generic resin that fills the budget aisle. This is the right tier for a whole-extract bottle. It loses to the 5-Loxin / AprèsFlex picks only because it standardises to total boswellic acids rather than a named AKBA-enriched fraction, so AKBA content isn't separately guaranteed.
At 2-3 caps daily the 500 mg extract reaches the ~1,000 mg/day standardised-extract window Kimmatkar 2003 used (~333 mg three times daily). A sensible serving hits the trial dose without forcing six caps. Single-cap dosing is below the window, but the label is honest about the multi-cap protocol.
Manufactured in GMP-certified facilities under NOW's in-house analytical QC labs — among the most consistent operations in the mass-market tier across a 30-plus-year track record. For an adulteration-prone botanical extract that's a meaningful fraud filter at this price point.
Roughly $11/month and about $0.09 per cap — the cheapest properly standardised whole boswellia extract on the list. Even at 3 caps/day it stays near the bottom of the category's productive cost range, which is the whole point of a first-bottle pick.
Adds a turmeric co-factor — sensible, since curcumin (NF-κB) complements boswellia's 5-LOX inhibition on a separate pathway. Clean veg-cap format, no proprietary blend hiding the dose. The only knock: the 25 mg turmeric is a token amount, not a clinical curcumin dose.
“Standardised to 65% boswellic acids.”
A real, stated standardisation figure consistent with NOW's published supplement-facts panel — 65% of the extract weight as total boswellic acids, roughly 325 mg of acids per 500 mg cap. This is a genuine active spec, not the unstated resin content that dominates the budget aisle, and it's the headline reason this bottle outranks commodity boswellia.
“Supports a healthy inflammatory response and joint comfort.”
Boswellia's anti-inflammatory and joint benefits are backed by real RCTs — Kimmatkar 2003 (PMID 12622457) found a standardised extract reduced knee-OA pain and improved function versus placebo over 8 weeks. NOW's whole-extract bottle at the multi-cap trial dose sits squarely within that evidence base.
“With turmeric for added support.”
Turmeric is a sensible complementary co-factor — curcumin acts on NF-κB, a different pathway from boswellia's 5-LOX, so the combination is mechanistically sound. But the 25 mg here is a token amount, far below the clinical curcumin doses (hundreds of mg of a high-absorption form) that drive turmeric's own trial results. It nudges, it doesn't deliver a second clinical dose.
“GMP quality assured, in-house tested.”
NOW manufactures in GMP-certified facilities and operates its own analytical QC laboratories — a verifiable, 30-plus-year operation that publishes testing summaries. For an adulteration-prone botanical category this is a credible, real fraud filter, not marketing language.
Walk the budget boswellia shelf and most bottles say "Boswellia 500 mg" with no standardisation figure at all — that's raw resin, the form the trials didn't test. NOW's bottle costs a few dollars more and gives you a stated 65% boswellic-acid extract: roughly 325 mg of actual acids per cap, a real and honest active number. That single spec is the difference between buying the thing the evidence supports and buying powdered tree resin. It's the entire reason this is the default first-bottle pick.
The one precision gap: NOW standardises to the boswellic-acid family as a whole, not to a guaranteed AKBA percentage. The strongest trial (Sengupta 2008) used 5-Loxin enriched to ~30% AKBA, the single most potent fraction. If you want to match that material exactly, Life Extension 5-LOXIN (#2) is the buy. But AKBA enrichment is the expensive part of the category, and for a buyer who hasn't yet confirmed boswellia helps them, a tested 65% whole extract at $11 is the rational first move. Validate response here, upgrade to AKBA on round two if you want maximal precision.
The most common way buyers under-dose boswellia is taking a single cap and concluding it doesn't work. Kimmatkar 2003 used roughly 1,000 mg/day of standardised extract, split three times daily — so NOW's 500 mg cap needs 2-3 a day with food to reach the trial window. That makes the 120-cap bottle a 6-8 week supply, not a four-month one. Plan and price it accordingly: at three caps a day you'll reorder roughly every six weeks, which is also a natural point to reassess whether it's helping.
NOW adding turmeric shows the right instinct — boswellia (5-LOX) and curcumin (NF-κB) hit different inflammatory pathways and genuinely complement each other. But the 25 mg of turmeric in each cap is a fraction of a clinical curcumin dose, and plain turmeric without a bioavailability enhancer is poorly absorbed anyway. Treat it as a small bonus, not a reason to skip a dedicated curcumin product. If a real two-pathway formula is what you want, Terry Naturally Curamin (#3) does it properly with branded standardised actives.
Botanical extracts are one of the more adulteration-prone supplement categories — identity and potency fraud are real risks. NOW running its own analytical QC labs and manufacturing under GMP, with a multi-decade track record, is a genuine quality signal you're getting essentially for free at this price. You can pay roughly double for Pure Encapsulations (#4) and get a cleaner excipient panel, but not materially better boswellic-acid standardisation. The testing-per-dollar on this bottle is the best on the list.
NOW Boswellia Extract is what we recommend to any reader who wants one boswellia bottle to start with and doesn't want to get lost in AKBA percentages. The form is right (a genuinely standardised 65% boswellic-acid extract, not resin), the dose is reachable (2-3 caps hits the Kimmatkar 2003 window), the testing is right (GMP plus NOW's in-house labs), and the price (~$11/month) is the lowest on the list for standardised material. The turmeric co-factor is a sensible bonus even if it isn't a clinical curcumin dose. Two cases where you should look elsewhere: (1) you specifically want the AKBA-enriched extract the strongest trial used — Life Extension 5-LOXIN (#2) is the literal 5-Loxin material at the Sengupta 2008 dose; (2) you have a sensitive gut or want a clinical curcumin dose in the same bottle — Pure Encapsulations (#4) for the cleanest label, Terry Naturally Curamin (#3) for the two-pathway combo. For everyone else, this is the bottle. Take 2-3 caps with food, give it 2-4 weeks, and stack it with curcumin and omega-3 if you want the full three-pathway anti-inflammatory base.
Check NOW Foods · Standardised to 65% boswellic acids (250 mg) + turmeric · 120 veg caps on AmazonThe literal 5-Loxin AKBA-enriched material (~30% AKBA) the strongest trial used, dosed at the clinical 100 mg. The upgrade when you want maximal AKBA precision rather than a whole extract.
See it on the list →Clinician-grade hypoallergenic standardised extract with zero fillers or dyes. The right call if you react to excipients or want the cleanest possible label — at roughly double the price.
See it on the list →The cheapest standardised extract on the list at ~$8/month — still a real boswellic-acid extract, not resin. The pick if you want the lowest possible cost to test whether boswellia helps you.
See it on the list →Randomised, double-blind, placebo-controlled crossover trial in knee-osteoarthritis patients: a standardised Boswellia serrata extract significantly reduced knee pain, improved joint function, and increased walking distance versus placebo over 8 weeks, with good tolerability. The anchor trial for the ~333 mg three-times-daily standardised-extract protocol NOW's 2-3 cap dose targets.
Placebo-controlled trial of 5-Loxin (an AKBA-enriched Boswellia extract, ~30% AKBA) at 100 and 250 mg/day in knee osteoarthritis: significant, dose-related reductions in pain and improvements in physical function, with benefits appearing within as little as 7 days at the 250 mg dose. Defines the AKBA-enriched standard NOW's whole extract is measured against.
One free quiz · personalized AI Coach path · 4 missions this week. Build your character, build your life.
